Peroxisome proliferator-activated receptor-gamma agonists promote differentiation and antioxidant defenses of oligodendrocyte progenitor cells - PubMed (original) (raw)

Peroxisome proliferator-activated receptor-gamma agonists promote differentiation and antioxidant defenses of oligodendrocyte progenitor cells

Antonietta Bernardo et al. J Neuropathol Exp Neurol. 2009 Jul.

Abstract

Several lines of evidence suggest that peroxisome proliferator-activated receptor-gamma (PPAR-gamma) agonists may control brain inflammation and, therefore, may be useful for the treatment of human CNS inflammatory conditions. The PPAR-gamma agonists delay the onset and ameliorate clinical manifestations in animal demyelinating disease models, in which the beneficial effects are thought to be mainly related to anti-inflammatory effects on peripheral and brain immune cells. Direct effects on neurons, oligodendrocytes, and other CNS resident cells cannot be excluded, however. To analyze potential direct actions of PPAR-gamma agonists on oligodendrocytes, we investigated the effects of both natural (15-deoxy Delta prostaglandin J2) and synthetic (pioglitazone) PPAR-gamma agonists in primary cultures of rat oligodendrocyte progenitor cells. The PPAR-gamma agonists promoted oligodendrocyte progenitor cell differentiation and enhanced their antioxidant defenses by increasing levels of catalase and copper-zinc superoxide dismutase while maintaining the overall homeostasis of the glutathione system. Protective effects were abolished in the presence of the specific PPAR-gamma antagonist GW9662, indicating that they are specifically dependent on PPAR-gamma. These observations suggest that in addition to their known anti-inflammatory effects, PPAR-gamma agonists may protect oligodendrocyte progenitor cells by preserving their integrity and favoring their differentiation into myelin-forming cells. Thus, PPAR-gamma may promote recovery from demyelination by direct effects on oligodendrocytes.

PubMed Disclaimer

Similar articles

• Peroxisome proliferator-activated receptor γ agonists accelerate oligodendrocyte maturation and influence mitochondrial functions and oscillatory Ca(2+) waves.
  De Nuccio C, Bernardo A, De Simone R, Mancuso E, Magnaghi V, Visentin S, Minghetti L. De Nuccio C, et al. J Neuropathol Exp Neurol. 2011 Oct;70(10):900-12. doi: 10.1097/NEN.0b013e3182309ab1. J Neuropathol Exp Neurol. 2011. PMID: 21937914
• Rosiglitazone induces interleukin-1 receptor antagonist in interleukin-1beta-stimulated rat synovial fibroblasts via a peroxisome proliferator-activated receptor beta/delta-dependent mechanism.
  Moulin D, Bianchi A, Boyault S, Sebillaud S, Koufany M, Francois M, Netter P, Jouzeau JY, Terlain B. Moulin D, et al. Arthritis Rheum. 2005 Mar;52(3):759-69. doi: 10.1002/art.20868. Arthritis Rheum. 2005. PMID: 15751073
• Peroxisome proliferator-activated receptor-gamma agonists suppress iNOS expression induced by LPS in rat primary Schwann cells.
  Zhang F, Liu F, Yan M, Ji H, Hu L, Li X, Qian J, He X, Zhang L, Shen A, Cheng C. Zhang F, et al. J Neuroimmunol. 2010 Jan 25;218(1-2):36-47. doi: 10.1016/j.jneuroim.2009.10.016. Epub 2009 Nov 25. J Neuroimmunol. 2010. PMID: 19942298
• Peroxisome proliferator-activated receptors and acute lung injury.
  Cuzzocrea S. Cuzzocrea S. Curr Opin Pharmacol. 2006 Jun;6(3):263-70. doi: 10.1016/j.coph.2006.01.008. Epub 2006 Mar 31. Curr Opin Pharmacol. 2006. PMID: 16580256 Review.
• Peroxisome proliferator-activated receptor gamma agonists as therapy for chronic airway inflammation.
  Belvisi MG, Hele DJ, Birrell MA. Belvisi MG, et al. Eur J Pharmacol. 2006 Mar 8;533(1-3):101-9. doi: 10.1016/j.ejphar.2005.12.048. Epub 2006 Feb 3. Eur J Pharmacol. 2006. PMID: 16458290 Review.

Cited by

• Cumulative incidence and risk factors for radiation induced leukoencephalopathy in high grade glioma long term survivors.
  Terziev R, Psimaras D, Marie Y, Feuvret L, Berzero G, Jacob J, Dehais C, Bompaire F, Mueller W, Kinnersley B, Delattre JY, Idbaih A, Hoang-Xuan K, Sanson M, Ricard D. Terziev R, et al. Sci Rep. 2021 May 13;11(1):10176. doi: 10.1038/s41598-021-89216-1. Sci Rep. 2021. PMID: 33986314 Free PMC article.
• Synergistic activity of interleukin-17 and tumor necrosis factor-α enhances oxidative stress-mediated oligodendrocyte apoptosis.
  Paintlia MK, Paintlia AS, Singh AK, Singh I. Paintlia MK, et al. J Neurochem. 2011 Feb;116(4):508-21. doi: 10.1111/j.1471-4159.2010.07136.x. Epub 2011 Jan 19. J Neurochem. 2011. PMID: 21143599 Free PMC article.
• Evaluation of peroxisome proliferator-activated receptor agonists on interleukin-5-induced eosinophil differentiation.
  Smith SG, Hill M, Oliveria JP, Watson BM, Baatjes AJ, Dua B, Howie K, Campbell H, Watson RM, Sehmi R, Gauvreau GM. Smith SG, et al. Immunology. 2014 Jul;142(3):484-91. doi: 10.1111/imm.12280. Immunology. 2014. PMID: 24628018 Free PMC article.
• The interleukin-4/PPARγ signaling axis promotes oligodendrocyte differentiation and remyelination after brain injury.
  Zhang Q, Zhu W, Xu F, Dai X, Shi L, Cai W, Mu H, Hitchens TK, Foley LM, Liu X, Yu F, Chen J, Shi Y, Leak RK, Gao Y, Chen J, Hu X. Zhang Q, et al. PLoS Biol. 2019 Jun 21;17(6):e3000330. doi: 10.1371/journal.pbio.3000330. eCollection 2019 Jun. PLoS Biol. 2019. PMID: 31226122 Free PMC article.
• Peroxisome proliferator-activated receptor γ (PPARγ): A master gatekeeper in CNS injury and repair.
  Cai W, Yang T, Liu H, Han L, Zhang K, Hu X, Zhang X, Yin KJ, Gao Y, Bennett MVL, Leak RK, Chen J. Cai W, et al. Prog Neurobiol. 2018 Apr-May;163-164:27-58. doi: 10.1016/j.pneurobio.2017.10.002. Epub 2017 Oct 12. Prog Neurobiol. 2018. PMID: 29032144 Free PMC article. Review.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Ovid Technologies, Inc.
  • Silverchair Information Systems

• Medical

  • MedlinePlus Health Information